Posted by Nicholas Vukelja
on June 01, 2026
When it comes to protecting your wellness, you want something that actually works. Before bringing AIRiWEAR to market, we researched the effectiveness of the core UV-C LED technology uses and tested the prototype AIRiWEAR device.
Independent lab testing of the early device prototype measured how effectively the AIRiWEAR reduces aerosolized E. coli (a standard test bacteria) in a single pass – essentially, the percentage of bacteria neutralized the first time air travels through the device’s UV-C chamber. On the higher setting, it delivered an average 75.55% single-pass reduction. These were early prototype results using a 40 milliwatt (mW) LED. Our current AIRiWEAR model uses a significantly more powerful >80mW LED, which provides substantially stronger performance.
Research at Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL)demonstrates that the specific UVC LEDs used in AIRiWEAR can effectively inactivate SARS-CoV-2 with low doses of light in the right germicidal range.
We know that trust has to be earned. Purepath is committed to transparency and scientific rigorfor our products. Sharing these foundational lab test results is part of that commitment. Clinical trials are an important next phase. Those typically follow initial lab work because they are resource-intensive, involve real people and require careful preparation. We’re actively advancing this research path, so you can feel confident in the protection AIRiWEAR provides.
